Merck (MRK), has been coming down following news that its Covid pill likely isn't as effective as it has been previously thought.However, this doesn't change the fact the MRK has been doing a ...
Merck & Co., Inc. (NYSE:MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal valued at over $3 billion, aiming to strengthen its drug pipeline. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback